HideChilds = False
SystemName =

Building on a legacy of innovation, we’re dedicated to creating meaningful progress for people with hemophilia and other blood disorders.

Delivering innovative therapies


Hemophilia A


Read more >

Hemophilia B


Read more >


Delivering quality medicine

Read more >
* Bioverativ was created as a spin-off from Biogen’s hemophilia business and separated from Biogen effective February 1, 2017. Bioverativ is an independent, publicly-traded company, headquartered in Waltham, Massachusetts. During a temporary transition period, which includes time to allow Bioverativ to establish or transfer certain licenses related to ELOCTATE and ALPROLIX, each of Bioverativ and Biogen will have a relationship to the products.  Contact us with any questions.